Prosecution Insights
Last updated: September 17, 2026
Application No. 18/595,120

Encapsulation of Functional Additives in Partially-Open Microcapsules

Non-Final OA §103
Filed
Mar 04, 2024
Priority
Mar 03, 2023 — provisional 63/488,189
Examiner
TRUONG, QUANGLONG N
Art Unit
1615
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
SAS Nanotechnologies Inc.
OA Round
1 (Non-Final)
79%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allowance Rate
515 granted / 654 resolved
+18.7% vs TC avg
Strong +24% interview lift
Without
With
+23.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
54 currently pending
Career history
692
Total Applications
across all art units

Statute-Specific Performance

§101
4.3%
-35.7% vs TC avg
§103
55.4%
+15.4% vs TC avg
§102
10.9%
-29.1% vs TC avg
§112
18.1%
-21.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 654 resolved cases

Office Action

§103
DETAILED ACTION Status of Application Receipt of the Claim set, filed on 5/12/2026 is acknowledged. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-28 are pending. Election/Restrictions Applicant’s election, without specific traverse, of Group I (claims 1-12) drawn to a a plurality of partially-open, hollow reservoirs in the reply filed on 5/12/2026 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)). The restriction requirement is therefore made FINAL. Claims 13-28 are withdrawn from consideration as directed to a non-elected invention. Claims 1-12 are included in the prosecution. Claim Rejections – 35 U.S.C. 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-12 are rejected under 35 U.S.C. 103 as being unpatentable over Surwade et al (US20200016564A1) hereinafter Surwade. Regarding claims 1-12, Surwade is drawn to polymer-based partially-open, hollow reservoirs in the nano-size to micro-size range that encapsulate an additive, which can be released from the reservoirs using specific event stimuli such as reduction-oxidation and voltage change, or at will, using the same stimuli. This invention also relates to method preparing such reservoirs, and for releasing the additive. This invention further relates to matrix that comprises such reservoirs and the method of preparing such matrix. This invention also relates to applications, for example in corrosion inhibition, lubrication, and adhesion, that benefit from using such a controlled release of an additive (abstract). Surwade discloses a plurality of partially-open, hollow reservoirs: wherein a substantial number of said plurality of partially-open, hollow reservoirs comprises at least one encapsulant; wherein said plurality of partially-open, hollow reservoirs comprise a polymer comprising at least one conducting polymer; wherein a substantial number of said plurality of partially-open, hollow reservoirs have at least one opening on their surface, such that the average opening area, in the aggregate, of said plurality of partially-open, hollow reservoirs is from about 0.25% to about 50% of the surface area in the aggregate of said plurality of partially-open, hollow reservoirs; wherein the average size of said plurality of partially-open, hollow reservoirs is in the range of from about 200 nm to about 10,000 nm; wherein said at least one encapsulant releasably resides within said plurality of partially-open, hollow reservoirs [0023]. Surwade discloses wherein said at least one conducting polymer is selected from polyaniline-based polymer, polyaniline-based polymer derivatives, polypyrrole, polypyrrole based polymer, polypyrrole based polymer's derivatives, blends thereof, and mixtures thereof [0029]. Surwade discloses wherein said conducting polymer is the polyaniline-based polymer, comprising at least one of polyaniline, poly-o-toluidine, poly-o-methoxyaniline, poly-o-ethylaniline, and poly-2-ethoxyaniline [0030]. Surwade discloses wherein said encapsulant is selected from the group consisting of a corrosion inhibiting additive, a lubricant additive, an adhesive additive, a biocide additive, an antifouling additive, a pesticide additive, a drug delivery additive, a corrosion sensor additive, a fragrance releasing additive, a catalyst additive, an ink additive, a dye additive, an enzyme additive, a reactant additive, and combinations thereof [0033]. Encapsulants with many functionalities, vel non, can be added to a POHR. Such functional additives include: corrosion inhibiting additives; lubricant additives; adhesive additives; biocidal additives; anti-fouling additives; pesticide additive [0104]. Surwade discloses the POHR encapsulated with pesticide, achieve a controlled pesticide release and also enables pesticide release in response to change in pH, which improves the pesticide use by reducing waste and pollution. Examples of pesticides amenable to the POHR encapsulation of the present invention include pyrethroids such as bifenthrin, permethrin, deltamethrin, lambda cyhalothrin, cyfluthrin, or betacyfluthrin; organophosphates such as chlorpyrifos; limonoids such as azadirachtin or meliartenin; phenyl pyrazoles or oxadiazines such as indoxacarb; phthalic acid diamides such as flubendiamide and anthranilic diamides, carbamates such as carbaryl (1-naphthyl N-methylcarbamate), neonicotinoids or nitroguanidines such imidacloprid, thiomethoxam, clothianidin or dinotefuran; diacylhydrazines such as halofenozide; neonicotines such as floconamid; organophosphates such as trichlorfon and pyrazoles such as fipronil [0206-0207]. Surwade does not explicitly disclose each of the components of the composition in a single embodiment for an anticipation rejection. However, it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the teachings of Surwade, to arrive at the instant invention. One of ordinary skill in the art would have been motivated to do so because Surwade discloses all the required ingredients and for the same purpose (abstract) and Surwade discloses the POHR encapsulated with pesticide, achieve a controlled pesticide release and also enables pesticide release in response to change in pH, which improves the pesticide use by reducing waste and pollution [0206]. Further, one having ordinary still in the art would reasonably expect success in combining prior art elements according to known methods to yield predictable results, see MPEP 2141. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to QUANGLONG N TRUONG whose telephone number is (571)270-0719. The examiner can normally be reached on 8:00 am-5:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert A Wax can be reached on 571-272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /QUANGLONG N TRUONG/Examiner, Art Unit 1615
Read full office action

Prosecution Timeline

Mar 04, 2024
Application Filed
Aug 11, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12721934
CATIONIC NANODRUG, PREPARATION METHOD THEREFOR, AND DRUG-LOADED IMPLANTABLE MEDICAL DEVICE
4y 6m to grant Granted Sep 01, 2026
Patent 12721815
FREEZE-DRIED EXOSOME COMPOSITION AND USES THEREOF
3y 7m to grant Granted Sep 01, 2026
Patent 12691055
INCRETIN ANALOG-CONTAINING COMPOSITIONS AND USES THEREOF
2y 10m to grant Granted Jul 28, 2026
Patent 12678387
COMPOSITION FOR ALLEVIATING HAIR LOSS OR PROMOTING HAIR GROWTH
3y 11m to grant Granted Jul 14, 2026
Patent 12678411
Nanoformulations of Pazopanib, Compositions Comprising the Same and Methods of Treating Osteoarthritis
2y 7m to grant Granted Jul 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
79%
Grant Probability
99%
With Interview (+23.7%)
2y 3m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 654 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month